Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: reply to a rebuttal
| Autor: | M, Raps, F M, Helmerhorst, K, Fleischer, A, van Hylckama Vlieg, V A, Van Hylckama, B H, Stegeman, S, Thomassen, F R, Rosendaal, J, Rosing, B E P B, Ballieux, H A A M, Van Vliet |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Sex hormone-binding globulin Sex Hormone-Binding Globulin Internal medicine Contraceptive Agents Female medicine Humans Blood Coagulation Venous Thrombosis Thrombotic risk Gynecology biology Surrogate endpoint business.industry Hematology medicine.disease Thrombosis Human Reproduction [NCEBP 12] Venous thrombosis Endocrinology Embolism biology.protein Female business hormones hormone substitutes and hormone antagonists Protein C Hormone medicine.drug |
| Zdroj: | Journal of Thrombosis and Haemostasis, 11, 396-7 Journal of Thrombosis and Haemostasis, 11, 2, pp. 396-7 |
| ISSN: | 1538-7933 |
| Popis: | Kluft et al. question the design of our recent study regarding Sex Hormone-Binding Globulin (SHBG) as marker for the risk of venous thrombosis during use of hormonal contraceptives (1). They state that when measured only in women 'on-treatment', SHBG showed a very weak association with normalized activated protein C sensitivity ratios (nAPCsr) determined with the thrombin generation-based APC resistance test. Hence, in their opinion SHBG is not a surrogate marker for venous thrombosis. They claim this statement is supported by a recent publication of Stegeman et al. (2). © 2012 International Society on Thrombosis and Haemostasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text